Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson’s Disease
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product quality and infusion device master file. No clinical safety or efficacy issues identified.